Research opportunity to trial disease‑modifying therapies for Alzheimer’s disease
The NIHR Oxford Health Clinical Research Facility (OH CRF) is inviting people to take part in important new research studies exploring innovative treatments designed to slow the progression of Alzheimer’s disease.
These studies are testing potential disease‑modifying therapies that aim to target the underlying biology of Alzheimer’s, rather than just managing symptoms. By taking part, volunteers will help researchers better understand how these treatments work and whether they could offer new options for people living with the condition in the future.
Participation involves attending study visits at the Warneford Hospital in Oxford. Study activities may include intravenous (IV) infusions of the study drug, memory and thinking assessments, brain imaging such as MRI and PET scans, alongside blood tests and routine physical health monitoring. Participants are closely supported throughout and carefully monitored by an experienced research team.
People may be eligible to take part if they are aged between 50 and 90 and have a diagnosis of mild cognitive impairment or Alzheimer’s dementia. Taking part is entirely voluntary, and choosing not to participate will not affect any current care or treatment.
Oxford Health’s Honorary Consultant Psychiatrist and R&D Director Professor Vanessa Raymont says: “Research studies like these are vital to improving our understanding of Alzheimer’s disease and to developing treatments that could slow its progression. By taking part, volunteers are helping us move closer to therapies that may make a real difference for people living with Alzheimer’s, now and in the future.”
If you are interested in finding out more about these studies, please contact [email protected] to speak with the research team.
